Vyndaqel
Chemical Name | tafamidis meglumine |
Dosage Form | Capsule (oral; 20 mg) |
Drug Class | Miscellaneous |
System | Cardiovascular |
Company | FoldRx Pharmaceuticals |
Approval Year | 2019 |
Indication
- Vyndaqel is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.